Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 20 cents in ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q4 CY2024, with sales falling 32.8% year on year to ...

Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio forecasts modest sales growth in 2025, it remains ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results tomorrow after market ...

SoftBank disclosed a 20.45M share position in PacBio (PACB) and 14.67M share position in Recursion Pharmaceuticals (RXRX) in a regulatory ...

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Revenue of $39.2 million, a 33% ...

PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a ...

PacBio’s earnings surpassed the Zacks Consensus ... Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative ...

CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems and the early shipment of seven Vega benchtop platforms, which exceeded schedule. Full-year ...